Using TREM2 genetics to find new treatments for Alzheimer's disease
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers Disease
This study is looking at how a specific gene change might affect Alzheimer's disease and is exploring new ways to treat it, especially for people with mild to moderate symptoms, by using existing anti-inflammatory medications to help improve brain health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11075344 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific genetic variant, TREM2R47H, influences the progression of Alzheimer's disease (AD) and explores new treatment options. By targeting neuro-inflammation through microglia, the study aims to repurpose existing anti-inflammatory drugs and design combination therapies that could be effective in treating AD. Patients with mild to moderate AD may benefit from these therapies, as the research investigates how these drugs can alter disease-associated microglial activity. The approach combines advanced genetic analysis with pharmacological testing to identify potential new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mild to moderate Alzheimer's disease, particularly those carrying the TREM2R47H genetic variant.
Not a fit: Patients with severe Alzheimer's disease or those without the TREM2R47H variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for Alzheimer's disease that target inflammation and improve patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting neuro-inflammation for Alzheimer's treatment, indicating that this approach could be a viable pathway for new therapies.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Cheng, Feixiong — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Cheng, Feixiong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.